Compare NEOS S&P 500 High Income ETF (SPYI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NEOS S&P 500 High Income ETF vs Zoetis Inc — how do they compare? NEOS S&P 500 High Income ETF trades at $54.2, while Zoetis Inc trades at $73.7 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| SPYI | ZTS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $54.19 | $156.76 |
52-Week Low | $47.98 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPYI (NEOS S&P 500 High Income ETF) trades at $54.20, showing minimal daily movement with a 0.02% gain. The ETF employs an options overlay strategy on the S&P 500 to generate high monthly distributions, with recent dividends of $0.53-$0.54. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. The fund's primary appeal is its ability to provide substantial income while maintaining S&P 500 exposure.
SPYI offers investors a unique income-generating approach through its options strategy, currently yielding approximately 12%. However, concerns exist about whether distributions represent true income versus return of capital. The fund's performance depends heavily on market volatility for option premium generation, creating both opportunity and risk. Investors should weigh the high yield against potential principal erosion in low-volatility environments.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
